
A Cardiology Pharmacy Podcast reviewing recent cardiology literature with hosts @SchwietTMac & @val_smartan; podcast editing @tweetlessnathan
Joined September 2019
- Tweets166
- Following35
- Followers959
- Likes141
CardioScripts retweeted
Thank you @CardioScripts for letting me come back and talk a bit about all things bempedoic acid and #cholesterol management!!
Truly a pleasure and honor to be back!
Happy Fall! Fall into a great discussion of the CLEAR Outcomes trial as @JurgaTomek discusses the current landscape of cholesterol management! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
Who else could highlight their favorite trials while also referencing Back to the Future, Sound of Music, and Las Vegas?
It was as an absolute blast working with @CardioScripts ... links to both episodes below
CS: open.spotify.com/episode/0LH…
PTD: open.spotify.com/episode/6ap…
ICYMI: The CardioScripts crew joined @PharmacyToDose podcast creator and host, @TweeetinPete, to discuss his Top 3 Trials in cardiology. Listen to our discussion with Nick on CardioScripts and find the full episode on the Pharmacy to Dose podcast! 💊🫀💉
apple.co/346sc9q
CardioScripts retweeted
Favorite landmark trial: VHeFT 1: started the avalanche of GDMT data as the 1st therapy to have proven benefit...only to be outdone shortly thereafter by the ACEI trials.
CardioScripts retweeted
The CAST trial! A lesson in the temptation of the inferential leap. “if we stop the arrhythmias-->we'll stop sudden deaths.” A reminder when reacting to surrogates, risk markers etc
Plus the investigators' courage to randomize and study an established practice
CardioScripts retweeted
UHCOP's @val_smartan talks results of DELIVER trial on diabetes drug dapagliflozin in heart failure patients with cardiology pharmacy specialist @JurgaTomek in fresh @CardioScripts episode
Take a break from debating if it's too early to listen to Christmas music (is it?) and check out the newest CardioScripts episode with @JurgaTomek and his thoughts on the DELIVER trial. It's a pretty sweet episode! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
Had an absolute blast recording this episode! Thank you @CardioScripts for letting me ramble a bit about heart failure and what not. – at Ann Arbor, MI
Take a break from debating if it's too early to listen to Christmas music (is it?) and check out the newest CardioScripts episode with @JurgaTomek and his thoughts on the DELIVER trial. It's a pretty sweet episode! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
🚨It’s finally here! #PARADISEMI 🚨
Post-MI, ACE/ARB should still be standard of care for new systolic dysfunction. And PLEASE start that MRA before discharge in patients meeting EPHESUS criteria.
@accpcardprn @CardioScripts
#PARADISEMI ARNI in Acute Myocardial Infarction out in @NEJM by Prof Marc Pfeffer et al.
nejm.org/doi/full/10.1056/NE…
@EldrinL @gabrielsteg @OtavioBerwanger @scottdsolomon @MajaCikes @markcpetrie20 @Drroxmehran @DLMann_MD @cbgranger
Special congrats @BrighamFellows #DrKarolaJering!
CardioScripts retweeted
Listened to it this morning. Masterclass on evaluating primary literature 🧐
👑 Check out our latest episode with @agoncha259 discussing the EMPEROR-Preserved trial👑 Is the reign of SGLT2 inhibitors here to stay? @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
In today's Pharmacy Grand Rounds, @MayoClinicHS PGY1 resident Bobby Schroeder makes heart failure do BOOM Sacu/Valsa with a review of this combo therapy. Follow along with live tweets here starting at 11am CST!
#TwitteRx @CardioScripts @accpcardprn
CardioScripts retweeted
In today's Pharmacy Grand Rounds, @MayoPharmRes PGY1 resident @pharmdiv makes our cardiology hearts go BOOM BOOM with updates in HFpEF treatment. Follow along with live tweets here starting at 11am CST!
#TwitteRx @mayoclinicshs @CardioScripts @accpcardprn
CardioScripts retweeted
I had so much fun chatting with @SchwietTMac @CardioScripts about PARADISE-MI. Spoiler alert: our post-ACS paradise includes more MRA use #cardiotwitter #EPHESUS @accpcardprn
Planning your summer vacation? Trouble finding paradise? Look no further as @StephDwyer21 discusses the PARADISE-MI trial. Sure to make you feel like you're in a paradise of your own! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
#ACC21 #ACCCVT Pharmacist Poster / Platform Presentations tonight starting at 5 PM CST! We have 200 people registered and LOTS of fabulous research lined up. Last chance to register below. See everyone tonight! @beaverspharmd @olivia_krz @SajniPatel2
okranzacc.wufoo.com/forms/pf…
CardioScripts retweeted
So glad you are back. I enjoy listening during my car ride to and from work. Keep up the great work ! @accpcardprn @ACCP @ASHPOfficial
The CardioScripts team is back! Check out our latest trailer and get ready for more literature crusading with great episodes and amazing guests! @accpcardprn apple.co/346sc9q
CardioScripts retweeted
This week's ACCP CARDS PRN “Teaching Tuesday” infographic, created by member @saraward_rx, is on the LVAD. Students & residents, what are your experiences in the care of patients with LVADs? Comment below! #cardiotwitter
CardioScripts retweeted
Q: Based on the results of the TRITON-TIMI 38 trial, which two subgroups benefitted from prasugrel over clopidogrel without an increase in bleeding events? #BCCP #BoardPrep
17%STEMI + Female
10%Diabetes + HLD
9%Female + Prior CVA
64%Diabetes + STEMI
263 votes • Final results CardioScripts retweeted
Just one of the many great takeaways in this podcast:
While SGLT2i’s have many benefits in our HF patients, we should first always take into consideration our patient’s specific goals & what their idea of a good QOL is. 👏🏻
New year, new episode, same reigning drug class. Don't miss out as @tedberei discusses the EMPEROR-Reduced trial and SGLT2 inhibitors! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
Thanks again for having me! – at Wisconsin, USA
New year, new episode, same reigning drug class. Don't miss out as @tedberei discusses the EMPEROR-Reduced trial and SGLT2 inhibitors! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
Awesome podcast @tedberei @val_smartan @SchwietTMac, thanks! Question: why do you think that DAPA-HF showed a mortality reduction but not EMPEROR-reduced? Does that impact your decision on which drug to choose in HFrEF? What if they have ASCVD + HFrEF? #cardiotwitter @twitteRx
New year, new episode, same reigning drug class. Don't miss out as @tedberei discusses the EMPEROR-Reduced trial and SGLT2 inhibitors! @accpcardprn
apple.co/346sc9q
CardioScripts retweeted
Give this one a listen #cardiotwitter friends. And kudos on the gif selection @CardioScripts 👌
New year, new episode, same reigning drug class. Don't miss out as @tedberei discusses the EMPEROR-Reduced trial and SGLT2 inhibitors! @accpcardprn
apple.co/346sc9q
























